Abstract:Background: Despite improved outcomes with the introduction of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor EGFR-activating mutations, unfortunately most patients eventually develop drug resistance. We and others recently reported that AXL activation confers acquired and intrinsic EGFR TKI resistance and represents a bypass resistance mechanism analogous to MET amplification in a subset of patients. This study aims to better assess the mechanisms whereby specific AXL inhibitors overcome such EGFR TKI resistance in NSCLC. Methods: AXL inhibitors including MGCD265 (glesatinib), MGCD516 (sitravatinib) and R428 (BGB-324) alone or in combination with erlotinib were used to test the inhibitory effect on EGFR TKI resistant NSCLC cells. Subsequently, the effects of single or combinational treatment on cell cycle and apoptosis were assessed. Then, RNA sequencing study was conducted to evaluate the dynamic gene expression profile changes and consequently based on key cellular pathway alterations studies of migration and EMT were pursued. Results: Administration of AXL inhibitors in combination with erlotinib significantly inhibited the growth of erlotinib-resistant NSCLC cells through potently inducing G2-M cell cycle arrest and enhancing apoptosis, relative to single agent treatment. RNA-sequencing analysis identified that several groups of genes enriched in cell survival inhibition or apoptosis promotion were upregulated, whereas genes enriched in DNA replication and repair, cell cycle and cell division were downregulated in cells treated with the combination of erlotinib and AXL inhibitor. Lastly, in line with pathway alterations indicating impaired migration, experiments showed reduced migration and EMT upon combination therapy. Conclusions: Our results indicate that effective blockade of the AXL pathway may represent a novel strategy to overcome EGFR TKI resistance for the treatment of biomarker-selected subsets of NSCLC patients.

CCL2 Promotes EGFR-TKIs Resistance in Non-Small Cell Lung Cancer Via the AKT-EMT Pathway

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Β-Catenin Overexpression is Associated with Gefitinib Resistance in Non-Small Cell Lung Cancer Cells.

[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].

CCL2 influences the sensitivity of lung cancer A549 cells to docetaxel.

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression

CCL2-SQSTM1 positive feedback loop suppresses autophagy to promote chemoresistance in gastric cancer

TROY Modulates Cancer Stem-Like Cell Properties and Gefitinib Resistance Through EMT Signaling in Non–Small Cell Lung Cancer

CCL2 promotes metastasis and epithelial–mesenchymal transition of non‐small cell lung cancer via PI3K/Akt/mTOR and autophagy pathways

Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer

Targeting CCL2/CCR2 signaling overcomes MEK inhibitor resistance in Acute Myeloid Leukemia

The Role of Axl in Drug Resistance and Epithelial-to-mesenchymal Transition of Non-Small Cell Lung Carcinoma.

Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance

CCL5 mediates target-kinase independent resistance to FLT3 inhibitors in FLT3-ITD-positive AML

The Role of ARL4C in Erlotinib Resistance: Activation of the Jak2/Stat 5/Β-Catenin Signaling Pathway

Implication of Epithelial-Mesenchymal Transition in IGF1R-induced Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer

Acquisition of EGFR TKI resistance and EMT phenotype is linked with activation of IGF1R/NF-κB pathway in EGFR-mutant NSCLC.

Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway

Integrin beta 3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway

Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells

CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis